Brief: Inventiva Says Its R&D Capabilities And Objectives Remain Unaltered

Inventiva SA

31/10/2022 07:16

Oct 31 (Reuters) - Inventiva SA  IVAA.PA :
    * INVENTIVA PROVIDES AN UPDATE ON THE DEVELOPMENT OF
CEDIROGANT BY
ABBVIE
    * COMPANY'S CASH RUNWAY, INCLUDING IS NOT IMPACTED BY
DISCONTINUATION OF CEDIROGANT CLINICAL PROGRAM
    * CASH RUNWAY SHOULD ALLOW TO FUND AS PREVIOUSLY ANNOUNCED
OPERATIONS THROUGH Q4 2023
    * INVENTIVA'S R&D CAPABILITIES AND OBJECTIVES REMAIN
UNALTERED

Source text for Eikon:  ID:nGNE7zynL2 
Further company coverage:  IVAA.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))